John Crowley, Amicus chairman and CEO

In an­tic­i­pa­tion of PhI­II tri­al re­sults, Am­i­cus pares down old debt with $400 mil­lion loan

Am­i­cus re­ceived a healthy heap­ing of good news last month when an­a­lysts threw cold wa­ter on Sanofi’s late-on­set Pompe dis­ease ERT, af­ter a Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.